Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial - Archive ouverte HAL Access content directly
Journal Articles Haematologica Year : 2016

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

, (1) , , , , , , , , ,
1
C. Willekens
  • Function : Author
A. Renneville
  • Function : Author
P. Cornillet-Lefebvre
C. Pautas
  • Function : Author
R. Guieze
  • Function : Author
N. Ifrah
  • Function : Author
H. Dombret
  • Function : Author
E. Jourdan
  • Function : Author
C. Preudhomme
  • Function : Author
N. Boissel
  • Function : Author

Abstract

In t(8;21)(q22;q22) acute myeloid leukemia, the prognostic value of early minimal residual disease assessed with real-time quantitative polymerase chain reaction is the most important prognostic factor, but how long-term minimal residual disease monitoring may contribute to drive individual patient decisions remains poorly investigated. In the multicenter CBF-2006 study, a prospective monitoring of peripheral blood and bone marrow samples was performed every 3 months and every year, respectively, for 2 years following intensive chemotherapy in 94 patients in first complete remission. A complete molecular remission was defined as a (RUNX1-RUNX1T1/ABL1)×100 ≤ 0.001%. After the completion of consolidation therapy, a bone marrow complete molecular remission was observed in 30% of the patients, but was not predictive of subsequent relapse. Indeed, 8 patients (9%) presented a positive bone marrow minimal residual disease for up to 2 years of follow-up while still remaining in complete remission. Conversely, a peripheral blood complete molecular remission was statistically associated with a lower risk of relapse whatever the time-point considered after the completion of consolidation therapy. During the 2-year follow-up, the persistence of peripheral blood complete molecular remission was associated with a lower risk of relapse (4-year cumulative incidence, 8.2%), while molecular relapse confirmed on a subsequent peripheral blood sample predicted hematological relapse (4-year cumulative incidence, 86.9%) within a median time interval of 3.9 months. In t(8;21)(q22;q22) acute myeloid leukemia, minimal residual disease monitoring on peripheral blood every 3 months allows for the prediction of hematological relapse, and to identify patients who could potentially benefit from intervention therapy.

Dates and versions

inserm-01817446 , version 1 (18-06-2018)

Identifiers

Cite

C. Willekens, O. Blanchet, A. Renneville, P. Cornillet-Lefebvre, C. Pautas, et al.. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica, 2016, 101 (3), pp.328 - 335. ⟨10.3324/haematol.2015.131946⟩. ⟨inserm-01817446⟩
21 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More